Adage Capital Partners’s Sutro Biopharma STRO Stock Holding History

Adage Capital Partners’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-200,000	Closed	-$4.98M	–	1085
2026 Q1	$4.98M	Hold	200,000	–	–	0.01%	775
2025 Q4	$2.31M	Hold	200,000	–	–	﹤0.01%	825
2025 Q3	$1.74M	Hold	200,000	–	–	﹤0.01%	816
2025 Q2	$1.43M	Hold	200,000	–	–	﹤0.01%	778
2025 Q1	$1.3M	Hold	200,000	–	–	﹤0.01%	783
2024 Q4	$3.68M	Sell	200,000 -25,013	-11%	-$764K	0.01%	745
2024 Q3	$7.79M	Buy	225,013 +25,013	+13%	+$980K	0.01%	664
2024 Q2	$5.86M	Hold	200,000	–	–	0.01%	693
2024 Q1	$11.3M	Sell	200,000 -246,780	-55%	-$10.9M	0.02%	578
2023 Q4	$19.2M	Buy	446,780 +136,267	+44%	+$4.32M	0.04%	432
2023 Q3	$10.8M	Buy	310,513 +287,941	+1,276%	+$12.5M	0.02%	545
2023 Q2	$1.05M	Buy	22,572 +17,000	+305%	+$846K	﹤0.01%	767
2023 Q1	$257K	Buy	+5,572	New	+$354K	﹤0.01%	830
2022 Q1	–	Sell	-16,000	Closed	-$2.38M	–	1131
2021 Q4	$2.38M	Sell	16,000 -11,500	-42%	-$2.06M	﹤0.01%	864
2021 Q3	$5.2M	Sell	27,500 -5,000	-15%	-$951K	0.01%	829
2021 Q2	$6.04M	Sell	32,500 -12,530	-28%	-$2.45M	0.01%	795
2021 Q1	$10.2M	Sell	45,030 -2,470	-5%	-$586K	0.02%	665
2020 Q4	$10.3M	Sell	47,500 -25,000	-34%	-$4.14M	0.02%	582
2020 Q3	$7.29M	Hold	72,500	–	–	0.02%	573
2020 Q2	$5.63M	Buy	72,500 +30,000	+71%	+$2.88M	0.01%	605
2020 Q1	$4.33M	Buy	42,500 +40,000	+1,600%	+$4.2M	0.01%	591
2019 Q4	$275K	Buy	+2,500	New	+$258K	﹤0.01%	706

Other funds holding STRO

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Adage Capital Partners's STRO Position: Q2 2026 in Review

Adage Capital Partners sold out of Sutro Biopharma (STRO) in Q2 2026, closing a stake of 200,000 shares — an estimated $4.98M sold.

Adage Capital Partners first reported a position in STRO in Q4 2019 and held it in 22 quarters. The position peaked at $19.2M in Q4 2023. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

Adage Capital Partners reported no remaining Sutro Biopharma position as of Q2 2026 after selling out during the quarter.
Adage Capital Partners sold 200,000 Sutro Biopharma shares in Q2 2026, an estimated $4.98M.
Adage Capital Partners first reported a position in Sutro Biopharma in Q4 2019 and held it in 22 quarters.
Adage Capital Partners's Sutro Biopharma position peaked at $19.2M in Q4 2023.
100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.